Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2021

Primary Completion Date

September 16, 2021

Study Completion Date

December 10, 2021

Conditions

GoutHyperuricemia

Interventions

DRUG

LC350189 Tablet

Subject will receive an LC350189 Tablet as single dose on Day 1 or Day 5

DRUG

LC350189 Capsule

Subject will receive an LC350189 Capsule as single dose on Day 1 or Day 5

Trial Locations (1)

PPD, Las Vegas